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ABSTRACT

SEPARATE AND JOINT ANALYSIS OF LONGITUDINAL AND
SURVIVAL DATA
Deepthi Rajeev
Department of Statistics
Master of Science

Chemotherapy is a method used to treat cancer but it has a number of sideeffects. Research conducted by the Department of Chemical Engineering at BYU
involves a new method of administering chemotherapy using ultrasound waves and
water-soluble capsules. The goal is to reduce the side-effects by localizing the delivery
of the medication. As part of this research, a two-factor experiment was conducted
on rats to test if the water-soluble capsules and ultrasound waves by themselves have
an effect on tumor growth or patient survival.
Our project emphasizes the usage of Bayesian Hierarchical Models and WinBUGS to jointly model the survival data and the longitudinal data—mass. The
results of the joint analysis indicate that the use of ultrasound and water-soluble
microcapsules have no negative effect on survival. In fact, there appears to be a positive effect on the survival since the rats in the ultrasound-capsule group had higher
survival rates than the rats in other treatment groups. From these results, it does
appear that the new technology involving ultrasound waves and microcapsules is a
promising way to reduce the side-effects of chemotherapy.
It is strongly advocated that the formulation of a joint model for any longitudi-

nal and survival data be performed. For future work for the ultrasound-microcapsule
data it is recommended that joint modeling of the mass, tumor volume, and survival
data be conducted to obtain additional information.
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Chapter 1
INTRODUCTION

Chemotherapy is a method used to treat cancer; unfortunately, it has many
side-effects. Research conducted by the Department of Chemical Engineering at BYU
involves a new method of administering chemotherapy using ultrasound waves and
microcapsules (Pitt 2003) to reduce these side-effects by localizing the delivery of
the medication. As part of this research, a study was carried out to test if watersoluble capsules and ultrasound waves had an effect on the growth of the tumors by
themselves. The study was a two-factor experiment conducted over 12 weeks using
rats that were induced with tumors in both legs. The anti-cancer drug was not a part
of the experiment and hence the rats were not given any chemotherapy.
The three main questions to be answered by the experiment are:
• Does the ultrasound affect the tumor growth, mass, or survival of the rat?
• Does the microcapsule affect the tumor growth, mass, or survival of the rat?
• Do the ultrasound and the microcapsule interact to affect the tumor growth,
mass, or survival of the rat?
The study was longitudinal (Verbeke and Molenberghs 2001) because mass and
tumor volume were collected on each rat over a period of time. It is very likely that
the measurements taken over time are not independent.
Mass, tumor volume, and the survival of the rats could be analyzed separately
using appropriate longitudinal and survival analysis methods (Cox 1972; Verbeke
and Molenberghs 2001). In general, this is a reasonable approach. Software packages
like SAS (SAS 2006) have procedures such as proc mixed and proc lifereg to model
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longitudinal data and survival data. However, if the longitudinal data are correlated
with survival, joint analysis may yield more information.
Recently, the joint analysis of both longitudinal and survival data has been proposed (Tsiatis et al. 1995; Wulfsohn and Tsiatis 1997; Henderson et al. 2000; Bowman
and Manatunga 2005). The analysis of the data using a joint model instead of separate models will result in unbiased and more efficient estimates. Joint modeling is
accomplished using latent variables that link the longitudinal models and the survival
models together. Guo and Carlin (2004) demonstrated a Bayesian approach to the
joint modeling of one longitudinal model and one survival model using WinBUGS.
The purpose of this study is to conduct the separate analyses of mass, tumor
volume, and survival, and in addition, the joint analysis of mass and survival for the
ultrasound-microcapsule data. The work will extend that of Guo and Carlin (2004)
in that the longitudinal mass model in the ultrasound-microcapsule data involves a
first-order autocorrelation structure for weekly weights. Results for the separate and
joint analyses will be compared.

2

Chapter 2
LITERATURE REVIEW

2.1

Micelles and Ultrasound in Chemotherapy
Cancer is a disease where cells multiply continuously because of mutations in

the DNA. Since cells produce DNA, these affected cells also produce DNA at a faster
rate than normal. Thus, drugs that hinder the production of DNA in turn affect the
cancer cells. However, since it has not been possible so far to determine a unique
feature that exists only in cancer cells, other cells that are healthy are also affected
by the drug. For instance, certain cells in the stomach lining and hair follicles also
multiply faster than the other cells and therefore, the anti-cancer drugs would disrupt
the DNA production in these cells too. This results in side-effects such as hair loss
or stomach problems for people under chemotherapy (DeVita 2001).
Research conducted by a group at the Department of Chemical Engineering at
BYU aims to determine whether localizing the effect of the anti-cancer drug would
result in a reduction of these side-effects (Pitt 2003). Water soluble plastics, called
micelles, made of polyethylene oxide and polypropylene oxide, are a self-assembled
collection of molecules. They possess an important property that renders them useful
for the purpose of this study—when introduced into water, they spontaneously form
tiny plastic spheres. Also, it has been found that an anti-cancer drug called doxorubicin is averse to water. Hence, when both micelles and the drug are mixed in water
the drug seeks protection in the spheres.
Plastic spheres that act as a carrier for the drug are injected into the patient
and low-frequency ultrasound waves are applied at the tumor site. This results in the
bursting of the capsules and the drug is released in the affected area alone. However, it
is not known whether micelles and ultrasound waves by themselves or in combination
3

with each other have an effect on the health and survival of the patient.

2.2

Mixed Models
A mixed model contains both fixed and random effects. For instance, the four

treatments (no ultrasound and no carrier, no ultrasound with a carrier, ultrasound and
no carrier, and ultrasound and carrier) in the ultrasound-microcapsule data constitute
a fixed factor, but the rats under consideration were randomly selected.
In general, a mixed model is of the form:
Y = Xβ + Zδ + ,
where X is the matrix of known values of the fixed predictors, Z is the matrix of known
values of the random factors, β is the vector of unknown coefficients for the fixed
effects, δ is the vector of unknown random effects, and  is the vector of errors (Littell
et al. 2005). In the standard mixed model, δ is distributed as a multivariate normal
with mean vector 0 and covariance matrix G and  is distributed as a multivariate
normal with mean vector 0 and covariance matrix R. G and R are required to be
positive definite matrices because they represent variance-covariance matrices. In
many models, R = σ 2 I. The vectors δ and  are usually assumed to be independent;
thus, the covariance matrix of Y is V = ZGZ 0 + R. Hence, Y is distributed as a
multivariate normal with mean vector, Xβ, and covariance matrix, V .
G, R, and V are functions of unknown parameters that can be estimated using
either the method of Maximum Likelihood (ML) or Restricted Maximum Likelihood
(REML). Once the estimate V̂ has been obtained, the estimate of β is given by
β̂ = (X 0 V̂ −1 X)− X 0 V̂ −1 Y and the approximate variance of β̂ is (X 0 V̂ −1 X)− .
The SAS procedure, proc mixed, is useful to analyze data when there are fixed
and random effects. The repeated statement in proc mixed defines the covariance
matrix, R, and the random statement in proc mixed defines the covariance matrix,
4

G (Littell et al. 2005; SAS 2006).
2.2.1

Longitudinal Data
Some experiments involve taking multiple measurements of a variable over a

period of time. These measurements are typically called longitudinal data or repeated
measurements. For instance, in the ultrasound-microcapsule data, mass and tumor
volume were measured weekly for each rat over a period of 12 weeks and hence are
longitudinal data. The basic model for a repeated measures design involves effects for
the experimental units, treatments, and time (Littell et al. 2005). The experimental
units are often assigned to different levels of a factor. Such a factor is called a
between-subjects factor. Similarly, since measurements are taken on an experimental
unit repeatedly over time, time is called a within-subjects factor.
A repeated measures model is a special case of the general mixed model. The
distinguishing feature of a repeated measures model is the specification of the covariance structure of the repeated measures. In a repeated measures model, the R matrix
reflects the covariance structure, and is usually not σ 2 I. The measurements within
an experimental unit are usually not equally correlated because measurements taken
closer in time tend to be highly correlated compared to measurements taken further
apart in time. Hence, selecting the right covariance structure for the data is very
important.
There are various model-fitting criteria that can be used to ascertain a reasonable covariance structure. The information criteria make use of the log likelihood of
the model and a penalty that is computed as a function of the number of parameters
in the model. For instance, the Akaike Information Criterion or AIC is computed as
AIC = 2k − 2ln(L), where k denotes the number of parameters in the model and
ln(L) is the log likelihood (Hirotuga 1974). The model with a smaller information
criterion value is preferred to a model with a larger information criterion value.
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2.3

Survival Analysis
Survival data are also called time to event data (Klein and Moeschberger 2003).

Generally, the data involve the time until some event occurs. The event could be the
death of the patient or the failure of the experimental unit. Time is an example of
survival analysis and event is an example of reliability analysis (Meeker and Escobar
1998).
Survival data almost always involve incomplete information and hence cannot be
analyzed using the basic modeling techniques. When an observation has incomplete
information, it is said to be a censored observation. There are three kinds of censoring: right censoring, left censoring, and interval censoring (Klein and Moeschberger
2003). Observations that do not fail during the measurement or observation period
are said to be right- censored. This could happen if a patient survives through the
experiment and is still living when the experiment concludes. An observation is also
right-censored if a patient leaves the experiment for some reason not connected with
survival. Observations that are known to have failed before a certain time are called
left-censored. Interval censoring is a more general type of censoring. When an event
is known to have occurred within an interval of time, the observation is said to be
interval censored.
Formally, if T represents the failure time of an experimental unit, the survivor
function is defined as
S(t) = P (T > t),
where t ∈ (0, ∞). The hazard function, defined as
λ(t) = lim+
∆t→0

P (t ≤ T < t + ∆t | T ≥ t)
,
∆t

specifies the unobserved instantaneous rate at which an event occurs for units surviving at time t. Thus, λ(t)∆t can be thought of as the probability that an individual
at risk will experience an event in time (t, t + ∆t). Although the hazard rate is not
6

observed, it controls the occurrence and timing of the event. The hazard function
fully specifies the survivor function because
λ(t) =

−dlogS(t)
.
dt

The Kaplan-Meier estimator or Product Limit Estimator provides a non-parametric
maximum likelihood estimate of the survivor function (Kaplan and Meier 1958). The
Kaplan-Meier estimate of S(t) is given as
ˆ =
S(t)

Y ni − d i
ti <t

ni

,

where ni corresponds to the number of observations at risk of failing just prior to
time ti ; di denotes the number of failures at time ti .
Parametric regression models are commonly applied to survival data. The
Weibull distribution, a generalization of the exponential distribution, is very flexible and widely used. Its hazard function is
λ(t) = θγ(θt)γ−1 ,
where θ > 0, γ > 0. The hazard is monotonically increasing for γ > 1, monotonically
decreasing for γ < 1, and constant for γ = 1.
The SAS procedure, proc lifereg, can be used to fit parametric models to right,
left, or interval-censored data (SAS 2006). The model is assumed to be of the form
y = Xβ + σ,
where y is the vector of logs of the survival times. X represents the matrix of predictor
variables, β denotes the vector of unknown regression coefficients,  is the vector
of errors assumed to come from a known distribution, and σ is an unknown scale
parameter. If survival times follow the Weibull distribution, the error distribution is
the extreme value distribution. When σ = 1, the Weibull distribution reduces to the
exponential distribution.
7

Similarly, survival times, yi , are assumed to follow the Weibull distribution with
parameters γ and θi = eXi θ . Klein and Moeschberger (Klein and Moeschberger 2003)
specify the relationships between the two formulations of the model.

2.4

Bayesian Analysis
Bayesian statistics is considered to have evolved from a paper by Rev.Thomas

Bayes published posthumously by Price in 1763 (Bayes 1763). Unaware of this paper,
Laplace independently developed the Bayes Theorem and extended its results in 1774.
A translated version of the paper by Laplace was published by Stigler (1986). The
term Bayesian was first used by Fisher in a note attached to a paper published in
1950 (Fisher 1950).
Bayes’ rule is:
π(θ | y) =

f (y | θ)π(θ)
,
f (y)

where π(θ | y) is called the posterior distribution of the vector of parameters, θ, given
the data (Gelman et al. 2004). f (y | θ) is the sampling distribution or the likelihood.
π(θ) denotes the prior distribution of the unknown parameters. f (y) is the marginal
distribution of y, and from the law of total probability f (y) can be calculated as
R
f (y) = f (y | θ) π(θ) dθ . f (y) is also called the normalizing constant. In his paper,
Bayes demonstrated the use of a uniform prior for a binomial likelihood (Bayes 1763).
Bayesian statistics involves the use of probability as a measure of uncertainty.
The unknown parameters are not considered to be fixed but rather random in nature;
hence, the parameters themselves have a distribution. If the posterior distribution
belongs to the same family of distributions as the prior distribution, then the prior is
said to be conjugate. Since the posterior distribution incorporates information from
the data, it will often be less varied and more peaked than the prior distribution.
Therefore, as the sample size increases, the effect of the prior distribution on the
posterior distrbution decreases. In cases where the prior distribution is difficult to
8

obtain, vague, flat or noninformative priors can be used.
Bayesian inference can usually be carried out by taking random draws from
the posterior distribution of the model parameters (Gelman et al. 2004). Before the
advent of computers, this was very difficult to implement. As a result, Bayesian statistics was not very practical in the 18th and 19th centuries. With the rediscovery in
the statistical literature of Markov Chain Monte Carlo (MCMC) simulation methods
such as Metropolis-Hastings and Gibbs sampling in the middle of the 20th century, it
became possible to draw samples from the posterior distribution. The term, Monte
Carlo refers to the simulation part of the algorithm. The technique involves the drawing of samples sequentially, with the distribution of the sampled draws dependent on
the previous value drawn. These draws form a Markov chain.
The Metropolis-Hastings algorithm is used to generate a sequence of samples
from any probability distribution p(x), requiring that the density can be calculated at
x (Metropolis et al. 1953; Hastings 1970). The Gibbs sampler developed by Geman
and Geman can be considered a special case of the Metropolis-Hastings algorithm
(Geman and Geman 1984). The algorithm is useful when the joint distribution is not
explicitly known but the conditional distribution of each parameter is known. An
initial starting point for the parameters is required and the algorithm involves a set
of iterative steps. At each iteration, a parameter is sampled from the conditional
distribution of all other parameters at their current value. After each iteration, the
value of the parameter is updated conditional on the current values of the other
parameters.
A specialized software package called WinBUGS implements the Bayesian analysis of complex statistical models using MCMC methods (Spiegelhalter et al. 2003).
WinBUGS uses Gibbs sampling when the priors are conjugate. When the priors
are non-conjugate, WinBUGS uses Adaptive Rejection sampling. Adaptive Rejection
sampling is a variation of Rejection sampling, a method that uses an envelope func-
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tion when it is difficult to sample from the actual posterior distribution. Adaptive
Rejection sampling makes use of a “squeezing function” and an envelope function that
together form lower and upper bounds to the density function. It has been shown
that as sampling proceeds, the squeezing function and the envelope function converge
to the density function (Gilks and Wild 1992). This useful technique is applied to
Bayesian models with non-conjugacy.

2.5

Joint modeling of Longitudinal Data and Survival Data
Experiments often generate both longitudinal data and survival data. There are

many methods to analyze the data separately (Cox 1972; Verbeke and Molenberghs
2001). However, when longitudinal data are correlated with survival data, fitting
separate models for each kind of data may not give complete information. Over recent
years, there has been considerable interest in the joint modeling of longitudinal data
and survival data.
In one approach, a two-stage modeling process was developed that dealt with
survival as a function of a covariate measured repeatedly. In the first stage, the covariate is modeled using growth curve models with random effects (Laird and Ware
1982). In the second stage, the modeled value is substituted into the partial likelihood for the Cox model with time-dependent covariates and the partial likelihood is
maximized. The purpose is to reduce the bias of the parameter estimates in the Cox
model (Tsiatis et al. 1995). However, this procedure has a main drawback—while
modeling the covariate process, survival information is not used.
To overcome this drawback, Wulfsohn and Tsiatis (Wulfsohn and Tsiatis 1997)
developed a method that maximized the joint likelihood from both the covariate
process and survival data simultaneously. That is, the parameters that describe the
covariate process and the parameters that describe the risk of failure as a function of
the covariate process are estimated at the same time. This results in the use of survival
10

information to get the estimates of the true covariate at any time. They use the Cox
model for the hazard of failure and assume that the true covariate value is given by
the growth model. The E-M algorithm is used to estimate the parameters of interest
(Dempster et al. 1977). In the E-step, the expected log-likelihood of the complete
data conditional on the observed data and the current estimate of the parameters
is computed. In the M-step, new parameter estimates are computed by maximizing
the expected log-likelihood. The algorithm involves iteration between these two steps
until the parameter estimates converge.
Henderson et al. (2000) proposed the use of an unobserved or latent bivariate
Gaussian process, W (t) = [W1 (t), W2 (t)], to link longitudinal data and survival data
in a clinical trial of schizophrenia patients. The longitudinal response variable was
a measure of the psychiatric disorder and the event was drop-out due to inadequate
response. They assumed that the longitudinal and event processes were conditionally
independent given W (t) and covariates. The correlation between W1 (t) and W2 (t)
describes the association between the longitudinal data and survival data. It was
assumed that W1 (t) and W2 (t) could be specified as a linear random effects model.
Model adequacy was checked by comparing simulated data and observed data. The
results showed good agreement, but the proposed method provided a complicated
solution to the problem.
Guo and Carlin (2004) developed a Bayesian implementation of the method used
by Henderson et al. (2000). They claimed that this approach was more straightforward to execute using the software WinBugs. Clinical data collected on 467 HIVinfected patients were used to demonstrate the Bayesian version of the joint modeling
of longitudinal and survival data. The study was conducted to evaluate the safety
and efficiency of two drugs in treating patients who were intolerant of AZT therapy.
The longitudinal response variable was CD4 count and the event was death. The
authors used non-informative prior distributions because they wanted to compare the
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results of the joint analysis obtained using WinBugs and the SAS procedure proc
nlmixed. As in Henderson et al. (2000), the association between the longitudinal
model and the survival model was accomplished using a latent zero-mean bivariate
Gaussian process. The results provide strong evidence that there is an association
between the longitudinal model and the survival model. Additionally, the results of
the joint model contradict the results of the two separate models. The further development and application of joint models for longitudinal and survival data is an area
of much current interest (Elashoff, R. and Li, G. and Li, N. 2006; Wang, J. L. and
Ding, J. 2006).

12

Chapter 3
METHODOLOGY

3.1

The Experiment
To determine the effects of the ultrasound and the carrier separately and in

combination an experiment was conducted without the anticancer drug. The experiment consisted of four treatment groups: no ultrasound and no carrier, no ultrasound
with carrier, ultrasound and no carrier, ultrasound and carrier. There were 30 rats of
similar age in the study, each rat being an experimental unit. Two rats died within
the first week, so they were excluded from the analysis. All the rats had a tumor
in both the left leg and the right leg. One leg was randomly chosen to receive the
treatment and the other leg was untreated. Sham ultrasound was applied to the chosen leg if the treatment level was “no ultrasound”. All of the rats were injected with
either the carier or saline. The rats were of both genders and were randomly assigned
to the four treatment groups. Each treatment group consisted of six to eight rats.
The carriers and the water soluble capsules used in the experiment were from a single
batch so that the variation between the carriers would be at a minimum.
The treatments were applied once a week for six weeks. The volume of the
tumors and the mass of the rats were measured for 12 consecutive weeks. Not all
rats survived until the end of the experiment. The number of days until death was
recorded for those rats that did not survive. Those rats that survived were euthanized
at the end of the experiment.
As part of the preliminary analysis, mass, treated tumor volume, and untreated
tumor volume for the four treatments were plotted against week (Figures 3.1, 3.2, and
3.3) for each rat. Kaplan-Meier survival curves were generated for each treatment for
male and female rats (Figure 3.4).
13

Figure 3.1: Mass profiles over time
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Figure 3.2: Treated tumor volume profiles over time
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Individual rats have characteristic weights that vary over time (Figure 3.1).
The apparent groupings in rat mass correspond exactly to gender, with female rats
being significantly smaller than male rats. Also, most of the rats seem to have a
tendency to lose weight shortly before death. Another obvious feature of Figure 3.1
is the apparent weight loss for every rat during week 7. This may be attributable to
a student or instrument calibration effect.
There is a clear linear trend in tumor volume for both treated and untreated
tumors (Figures 3.2, 3.3). Also, both treated and untreated tumor volume for most
rats seem to be increasing in a roughly parallel manner for all four treatments.
It appears that survival depends on the gender of the rat and the treatment
applied (Figure 3.4); female rats seem to have a better survival rate than male rats
and rats in the treatment with both the ultrasound and the carrier seem to have a
better survival rate than rats in the other three treatments groups.

3.2

Separate Analyses using SAS
Separate longitudinal models and survival models were fitted using the SAS

procedures— proc mixed and proc lifereg (SAS 2006).
Several longitudinal models for mass were considered and compared using AIC.
The final model had random intercepts for rats and a first-order autocorrelation
structure for weekly weights. Fixed predictor variables included treatments, week,
treatment-by-week interactions, treated leg (left or right), gender, and an indicator
variable for week 7. Code for SAS procedure proc mixed is included in Appendix
A(i).
Tumor volumes for both treated and untreated legs were analyzed jointly.
Again, several longitudinal models for tumor volume were considered and compared
using AIC. The final model had random intercepts and slopes among rats and between the legs of the same rat. Fixed predictor variables included treatments, week,
16

Figure 3.3: Untreated tumor volume profiles over time

Figure 3.4: Survival profiles for female (left) and male (right) rats
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treatment-by-week interactions, treated leg (indicator variable to denote if the left
or right leg was treated), gender, and leg (indicator variable to denote if the leg was
treated or untreated). Code for this model is included in Appendix A(ii).
The survival data was modeled using the SAS procedure proc lifereg (SAS
2006). The response variable was days to death and the explanatory variables were
treatment and gender. The code is found in Appendix A(iii).

3.3

Separate Analyses using WinBUGS
WinBUGS is a software package that is used for hierarchical Bayesian analysis

of statistical models (Spiegelhalter et al. 2003). Similar separate models were used
for mass, tumor volume and survival as in the SAS analyses.
Modeling the first-order autocorrelation structure in WinBUGS is slightly more
complicated than modeling it in SAS. WinBUGS uses the inverse of the variancecovariance matrix, called the precision matrix. To deal with this problem, we obtained
τ , the inverse of the first-order auto-regressive variance-covariance matrix. τ is
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where σ 2 is the variance and ρ is the autocorrelation coefficient.
A vague normal prior for the mean of the intercepts and a vague gamma prior
for the precision of the intercepts were used. All of the regression coefficients were
also assigned vague normal priors. ρ was considered to be uniformly distributed with
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parameters 1 and -1. σ −2 was assigned a vague gamma prior. The WinBUGS code
for the mass model is included in Appendix B(i).
Because, the initial mass of the rats ranged from about 150 grams to 350 grams
(Figure 3.1), our use of a normal prior with a standard deviation of 10000 is noninformative. Moreover, the results were similar when the model was analyzed with
different priors. It can be concluded that the priors used are indeed vague.
To specify a similar model for tumor volume to that used in SAS using WinBUGS, we assumed independence among rats and independence between legs within
individual rats. We specified random intercepts and slopes for rats and legs within
rats. The means of the intercepts for each rat and leg within each rat were assigned
vague normal priors and the precisions of the intercepts were assigned vague gamma
priors. Similarly, the means of the slopes for each rat and leg within each rat were
given vague normal priors and the precisions of the slopes were given vague gamma
priors. The fixed predictors were the same as those included in the SAS model and
their corresponding regression coefficients were assigned vague normal priors. The
WinBUGS code is included in Appendix B(ii).
The survival model that was analyzed using the SAS procedure proc lifereg
was fitted using WinBUGS. The response variable, days to death was drawn from
a Weibull distribution. The predictors were treatment and gender. The regression
coefficients were assigned vague normal priors. The code can be found in Appendix
B(iii).
The results of the models described above and a comparison of the SAS and
WinBUGS results will be discussed in the Results chapter.

3.4

Joint Analysis of Longitudinal Mass Data and Survival Data using WinBUGS
This section describes the joint modeling of the mass model and the survival

model. The two models were linked together using a latent variable, Ui , that denotes
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the random effects for the mass model that are specific to each rat (i = 1 to 28).
In particular, Ui denotes the deviations of the intercept for each rat from an overall
intercept. Because the mean of the deviations is zero, we specified a zero-mean normal
distribution for Ui with the precision drawn from a vague gamma prior distribution.
We then computed
Wi = δ U i
as a frailty term in the survival model. This links the mass model to the survival
model. The parameter δ measures the association between the submodels. The code
can be found in Appendix B(iv).
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Chapter 4
RESULTS

4.1

Longitudinal Results using SAS and WinBUGS
Table 4.1 displays the SAS and WinBUGS results of the mass model. The

WinBUGS results are based on a burn-in of the first 400,000 samples of a total of
1,000,000 samples drawn from the posterior distribution. A study of the trace and
density plots of the posterior distributions of the coefficients indicate that the results
are accurate and the MCMC algorithm converged. The plots of the coefficients of
treatment-by-week interaction and gender are included in Appendix C. The time
series plots based on 500 samples indicate reasonable mixing and are also included in
Appendix C. The results indicate that there is no treatment effect or treatment-byweek interaction effect but there is definitely a gender effect. Week 7 is also significant.
The estimate of the first-order autocorrelation in the WinBUGS model is reasonably
close to the estimate obtained using SAS. As seen in Table 4.1, the coefficients of all
the other parameters of the model in SAS using proc mixed and WinBUGS are also
reasonably close.
The results of the tumor volume model from SAS and WinBUGS are shown in
Table 4.2. The WinBUGS results are calculated after a burn-in of the first 400,000
samples from a total of 1,000,000 samples drawn from the posterior distribution. The
plots of the coefficients of treatment-by-week interaction and week are included in
Appendix D. The results show that there is a significant effect of week and there
is also a significant difference between the left tumor and the right tumor. The
WinBUGS results are extremely close to the SAS results with the exception of the
estimate of week. Both the estimates indicate a significant effect of week.
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Parameter
Intercept
Gender
Leg (left-right)
Treatment 2
Treatment 3
Treatment 4
Time
Treatment 2 * Time
Treatment 3 * Time
Treatment 4 * Time
Week 7
ρ

SAS
WinBUGS
Estimate Standard Error Posterior Mean Posterior Std. Dev.
161.95
11.23
158.30
13.48
106.58
7.73
106.60
8.36
2.66
7.29
2.82
7.90
0.46
13.42
0.46
14.97
-7.90
13.16
-7.46
14.67
25.68
13.36
25.98
14.89
1.90
1.02
2.03
1.21
-0.70
1.42
-0.86
1.68
1.41
1.36
1.33
1.60
1.33
1.35
1.24
1.59
-20.41
1.21
-20.46
1.63
0.94
0.03
0.88
0.03

Table 4.1: Mass model results using SAS and WinBUGS.

Parameter
Intercept
Gender
Leg (left-right)
Leg (treated-untreated)
Treatment 2
Treatment 3
Treatment 4
Week
Treatment 2 * Week
Treatment 3 * Week
Treatment 4 * Week

SAS
WinBUGS
Estimate Standard Error Posterior Mean Posterior Std. Dev.
-1.51
0.27
-1.18
0.17
0.24
0.24
0.24
0.24
0.63
0.22
0.63
0.22
-0.14
0.14
-0.14
0.15
-0.05
0.33
-0.04
0.32
0.08
0.32
0.08
0.32
0.12
0.33
0.11
0.32
0.33
0.03
0.17
0.01
0.03
0.04
0.03
0.04
0.07
0.04
0.07
0.04
0.01
0.04
0.01
0.04

Table 4.2: Tumor volume model results using SAS and WinBUGS.
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Parameter
Intercept
Gender
Treatment 2
Treatment 3
Treatment 4

Estimate
4.20
0.16
0.03
-0.03
0.29

SAS
Standard Error
0.01
0.02
0.02
0.02
0.03

WinBUGS
Posterior Mean Posterior Std. Dev.
4.22
0.08
0.15
0.09
0.01
0.10
-0.03
0.10
0.32
0.15

Table 4.3: Survival model results using SAS and WinBUGS.

4.2

Survival Results
This section describes the SAS and WinBUGS results of survival data. The

model in WinBUGS is analyzed using a burn-in of 400,000 samples from a total of
1,00,0000 draws from the posterior distributions of the parameter coefficients. Table
4.3 describes the results of SAS procedure proc lifereg and WinBUGS. Table 4.4
describes the median survival time with respect to treatment and gender.
Due to different parametrization in SAS and WinBUGS, the estimates obtained
in WinBUGS were converted to be consistent with the estimates obtained in SAS. This
was done by multiplying the WinBUGS coefficients by the negative of the inverse of
the Weibull shape parameter. The trace and density plots of the coefficients indicate
that the MCMC algorithm converged (Appendix E). The results indicate that rats in
the treatment with ultrasound and the carrier have a better survival rate than rats in
the other three treatments groups. Also, both the SAS and WinBUGS results indicate
SAS
Median
no ultrasound, no carrier
no ultrasound, carrier
ultrasound, no carrier
ultrasound, carrier

Female
74.38
77.10
72.27
99.45

Male
63.06
65.37
61.27
84.31

Female
74.77
75.63
72.41
103.40

WinBUGS
Male
64.26
64.97
62.37
88.71

Table 4.4: Median Survival times using SAS and WinBUGS.
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that the ultrasound and carrier treatment have a significant effect on survival.

4.3

Goodness of Fit
Goodness of fit was carried out for the non-Bayesian models. The results of

the separate models in SAS and WinBUGS were very similar, so it is reasonable to
assume that the goodness of fit evaluation of the SAS models would apply to the
Bayesian models.
A residual plot represents the difference between the observed response variable
and the predicted value. The residual plot (Figure 4.1) for the mass model was
constructed and from the plot it appears that there are no odd trends. In general, the
points seem to be fluctuating randomly around zero. In addition, the predicted values
for mass were plotted against the observed values (Figure 4.2). For the most part,
there appears to be a linear relationship between the predicted and observed values.
The fit of the survival model was checked using the Cox-Snell residual plot(Klein
and Moeschberger 2003) (Figure 4.3). This method involves the estimation of the
cumulative hazard function for a Weibull distribution and the Cox-Snell residuals.
For the most part, the plot indicates a reasonable fit.
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Figure 4.1: Residual plot for Mass model. Treatment 1: no ultrasound, no carrier,
Treatment 2: no ultrasound, carrier, Treatment 3: ultrasound, no carrier, Treatment
4: ultrasound, carrier
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Figure 4.2: Predicted plot for Mass model. Treatment 1: no ultrasound, no carrier,
Treatment 2: no ultrasound, carrier, Treatment 3: ultrasound, no carrier, Treatment
4: ultrasound, carrier

Figure 4.3: Cox-Snell Residual plot for Survival model
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4.4

Joint Results
This section describes the WinBUGS results of the joint analysis of mass and

survival data. The analysis is based on a burn-in of the first 100,000 samples from
a total of 350,000 samples drawn from the posterior distribution. Table 4.5 displays
the WinBUGS results of the joint model and the two separate models. A study of
the trace and density plots of the posterior distributions of the coefficients (Appendix
F) indicate that the results are accurate and MCMC algorithm converged. The time
series plots based on 500 samples indicate reasonable mixing. As seen in Table 4.5,
the estimates of the parameters of the separate models are similar to those of the
joint model.
In the separate analysis, the median survival times for the rats in the treatment
with the ultrasound and the carrier were much higher than the median survival times
for the rats in the other treatments. This is possibly because the rats in this treatment
group were larger than the rats in the other three treatment groups. The joint model
was fitted in the hope that this difference between the treatments in the survival
model would decrease once the mass of the rats was taken into account. The median
survival times from both the separate and the joint models are displayed in Table
4.6. The treatment with the ultrasound and the carrier continues to have the highest
median survival time.
The rats in the ulrasound, no carrier group had the lowest median survival time
in the separate model. In the joint model, the rats in the no ultrasound, carrier group
have the lowest median survival time. This is true for both male and female rats.
The estimated coefficient δ, which measures the association between mass and the
survival of the rat, is negative but not significant. Since the results of the joint model
were very close to the results of the separate model, no further goodness of fit was
conducted. Again, because the analyses of these models with different priors resulted
in similar estimates for the parameters, we think the priors used are indeed vague.
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Parameter

Intercept
Gender
Leg (left-right)
Treatment 2
Treatment 3
Treatment 4
Time
Treatment 2 * Time
Treatment 3 * Time
Treatment 4 * Time
Week 7
ρ
Intercept
Gender
Treatment 2
Treatment 3
Treatment 4
δ

Separate Analysis
Posterior
Posterior
Mean
Std. Dev
Mass Submodel
158.30
13.48
106.60
8.36
2.82
7.90
0.46
14.97
-7.46
14.67
25.98
14.89
2.03
1.21
-0.86
1.68
1.33
1.60
1.24
1.59
-20.46
1.63
0.88
0.03
Survival Submodel
4.22
0.08
0.15
0.09
0.01
0.10
-0.03
0.10
0.32
0.15
-

Joint Analysis
Posterior
Posterior
Mean
Std. Dev.
Mass Submodel
158.60
13.35
106.70
8.20
2.72
7.77
0.46
14.95
-7.49
14.62
26.01
14.88
2.01
1.23
-0.87
1.71
1.35
1.63
1.25
1.61
-20.43
1.62
0.89
0.02
Survival Submodel
4.22
0.11
0.04
0.12
-0.08
0.15
-0.01
0.15
0.32
0.18
-796.5
893.5

Table 4.5: Separate and Joint Analysis of Mass and Survival Submodels using WinBUGS.

Median
no ultrasound, no carrier
no ultrasound, carrier
ultrasound, no carrier
ultrasound, carrier

Separate
Female
74.77
75.63
72.41
103.40

Analysis
Male
64.26
64.97
62.37
88.71

Joint Analysis
Female
Male
70.84
67.91
64.67
62.14
69.44
66.87
97.87
93.76

Table 4.6: Median Survival times for Separate and Joint Models.
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Chapter 5
CONCLUSION

The results of the joint model demonstrate that the use of the ultrasound and
the carrier do not have any negative effects on the survival of the rats. In fact, the
rats who were in the treatment with the ultrasound and the carrier survived longer
than the rats in the other three treatment groups. The joint model was conducted in
the hope that the adjustment for the effect of mass on survival would account for the
increased survival in the ultrasound, carrier group. It was expected that the mean
survival times of all the rats would be similar in the joint model; however, this was
not the case.
Once the separate models were formulated using WinBUGS, the joint modeling
was accomplished fairly easily. However, formulating the separate models in WinBUGS to match the SAS results was quite a task. Accomodating the autocorrelation
structure of the weekly weights was diffcult in WinBUGS. Moreover, due to different parametrization of the Weibull distribution used in WinBUGS and SAS, it was
necessary to convert the WinBUGS results to be more consistent with the SAS results. Nevertheless, we agree with Guo and Carlin that conducting a joint analysis for
longitudinal and survival data is highly recommended and fairly easy to implement.
A method called the Bayesian χ2 test for goodness of fit for Bayesian models
was recently proposed by Johnson (2004). This method is considered better than
the posterior predictive method to test the fit of a model. The diagnostic used in
the Bayesian χ2 test for goodness of fit is related to the classical χ2 goodness of fit
statistic. It requires the allocation of observations to bins according to the value of
each observation’s conditional distribution function, conditional on a single parameter
value sampled from the posterior distribution. The implementation of this method
29

to the ultrasound-microcapsule data is highly recommended. It will be an extension
of the work of Johnson since the ultrasound-microcapsule data is multivariate.
The results of this experiment indicate that this new technology involving ultrasound waves and microcapsules is a promising way to reduce the side-effects of
chemotherapy. We recommend that the joint modeling of the mass model, tumor volume model, and the survival model should be performed to obtain a clearer picture
of the effect of the ultrasound and the microcapsules.
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Appendix A
SAS CODE

options ls=90 formdlim="#";
/*Importing the first Excel file*/
PROC IMPORT DATAFILE="c:\deepthi\project\rats1a.xls"
OUT=rats1 REPLACE;
RANGE="A3:J332";
GETNAMES=yes;
run;
/*Sorting the dataset*/
proc sort data=rats1;
by rat_name;
run;
/*Importing the second Excel file*/
PROC IMPORT DATAFILE="c:\deepthi\project\rats2a.xls"
OUT=rats2 REPLACE;
RANGE="B2:H33";
GETNAMES=yes;
run;
/*Sorting the dataset*/
proc sort data=rats2;
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by rat_name;
run;
/*Merging the two datasets by ratname*/
data mergeddata;
merge rats1 rats2;
by rat_name;
drop F6;
run;
proc sort data=mergeddata;
by treatment sex rat_name;
run;

/*Calculating volume*/
data merge2;
set mergeddata;
if leg_US = ’L’ then do;
lcmt1=left1cm;
lcmt2=left2cm;
rcmu1=right1cm;
rcmu2=right2cm;
end;
if lcmt1<lcmt2 then do;
tvolume=(lcmt1*lcmt1*lcmt2)/2;
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tlogv=log(tvolume);
end;
if lcmt1>lcmt2 then do;
tvolume=(lcmt2*lcmt2*lcmt1)/2;
tlogv=log(tvolume);end;
if rcmu1<rcmu2 then do;
uvolume=(rcmu1*rcmu1*rcmu2)/2;
ulogv=log(uvolume);
end;
if rcmu1>rcmu2 then do;
uvolume=(rcmu2*rcmu2*rcmu1)/2;
ulogv=log(uvolume);
end;
if leg_US = ’R’ then do;
lcmu1=left1cm;
lcmu2=left2cm;
rcmt1=right1cm;
rcmt2=right2cm;
end;
if lcmu1<lcmu2 then do;
uvolume=(lcmu1*lcmu1*lcmu2)/2;
ulogv=log(uvolume);
end;
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if lcmu1>lcmu2 then do;
uvolume=(lcmu2*lcmu2*lcmu1)/2;
ulogv=log(uvolume);
end;
if rcmt1<rcmt2 then do;
tvolume=(rcmt1*rcmt1*rcmt2)/2;
tlogv=log(tvolume);
end;
if rcmt1>rcmt2 then do;
tvolume=(rcmt2*rcmt2*rcmt1)/2;
tlogv=log(tvolume);
end;
run;

proc sort data=merge2;
by treatment rat_name tmtweek;
run;

data merge4;
set merge2;
leg=1;

/*treated=1*/

logv=tlogv;
output;
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leg=0;

/*untreated=0*/

logv=ulogv;
output;

data merge28;
set merge4;
if (rat_name=’H02’) or (rat_name=’H32’);
then delete;
run;
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(i). Mass model

data merge5;
set merge28;
week7=(tmtweek=7);
run;

proc mixed data=merge5 covtest;
class treatment rat_name leg_US;
model ratmass=sex leg_US treatment week7 tmtweek
treatment*tmtweek /ddfm=kenwardroger solution;
random rat_name;
repeated/subject=rat_name type=AR(1);
run;
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ii). Tumor Volume model
proc mixed data=merge28 covtest;
class sex leg_US leg treatment rat_name;
model logv=sex leg_US leg treatment tmtweek
treatment*tmtweek/ddfm=kenwardroger solution;
random intercept tmtweek/subject=rat_name type=vc;
random intercept tmtweek/subject=leg(rat_name) type=vc;
run;
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(iii). Survival model

proc lifereg data=merge28;
class treatment sex;
model days_to_death*status(0)=treatment sex/dist=weibull;
run;
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Appendix B
WINBUGS CODE

(i). Mass

model
{
c1<-(isigmasq)/(1-pow(rho,2))
c2<-(isigmasq)*(1+pow(rho,2))/(1-pow(rho,2))
c3<-isigmasq*(-rho)/(1-pow(rho,2))
for (i in 1:M)
{
for (j in 1:M)
{
a1[i,j]<-step(1-i)*step(1-j)
b1[i,j]<-step(i-M)*step(j-M)
c1a[i,j]<-step(i-j)*step(j-i)
c1b[i,j]<-(1 - step(1-i)*step(1-j))
c1c[i,j]<-(1 - step(i-M)*step(j-M))
d1a[i,j]<-step(1-i+j)*step(1-j+i)
d1b[i,j]<-(1-step(i-j))*step(j-i)
e1a[i,j]<-step(1-j+i)*step(1-i+j)
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e1b[i,j]<-(1-step(j-i))*step(i-j)
a[i,j]<-a1[i,j]*c1
b[i,j]<-b1[i,j]*c1
c[i,j]<-c1a[i,j]*c1b[i,j]*c1c[i,j]*c2
d[i,j]<-d1a[i,j]*d1b[i,j]*c3
e[i,j]<-e1a[i,j]*e1b[i,j]*c3
tau[i,j]<- a[i,j]+b[i,j]+c[i,j]+d[i,j]+e[i,j]
}
}
for(k in 1 : N)
{
rmass[k,1:M]~dmnorm(mu[k,1:M],tau[1:M,1:M])
for (l in 1:M)
{
mu[k, l] <- b0[k] + beta.c1*tmt2[k]+ beta.c2*tmt3[k] +
beta.c3*tmt4[k]+ 0*tmt1[k]+beta.c5*legtr[k]
+beta.c6*sex[k] +beta.c7*time1[l] +
beta.c8*tmt2[k]*time1[l] + beta.c9*tmt3[k]*time1[l]
+ beta.c10*tmt4[k]*time1[l] + beta.c11 *week7[l]
}
b0[k] ~ dnorm(beta.c0,beta.tau0)
}
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beta.c0 ~ dnorm(0.0,1.0E-8)
beta.c1 ~ dnorm(0.0,1.0E-8)
beta.c2 ~ dnorm(0.0,1.0E-8)
beta.c3 ~ dnorm(0.0,1.0E-8)
beta.c5 ~ dnorm(0.0,1.0E-8)
beta.c6 ~ dnorm(0.0,1.0E-8)
beta.c7 ~ dnorm(0.0,1.0E-8)
beta.c8 ~ dnorm(0.0,1.0E-8)
beta.c9 ~ dnorm(0.0,1.0E-8)
beta.c10 ~ dnorm(0.0,1.0E-8)
beta.c11 ~ dnorm(0.0,1.0E-8)
beta.tau0 ~ dgamma(0.0001,0.0001)
sigmatau0 <- 1/beta.tau0
rho ~ dunif(-1,1)
isigmasq ~ dgamma(0.0001,0.0001)

intercept <- beta.c0
treatment2 <- beta.c1
treatment3 <- beta.c2
treatment4 <- beta.c3
leg_left_right <- beta.c5
gender <- beta.c6
time <- beta.c7
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week_7 <- beta.c11
treatment2_time <- beta.c8
treatment3_time <- beta.c9
treatment4_time <- beta.c10
AR1 <- rho
}

# Data
list(time1=c(1,2,3,4,5,6,7,8,9,10,11,12), M=12, N=28,
rmass=structure(.Data=c(
.
.
.
.
.
.
.
.
),
.Dim=c(28,12)),
tmt1= c(0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,
0,0,0,0,0,1,1,0,0,1,0),
tmt2= c(0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,
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0,0,1,1,1,0,0,0,1,0,0),
tmt3= c(1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,
0,0,0,0,0,0,0,1,0,0,0),
tmt4= c(0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,
1,1,0,0,0,0,0,0,0,0,1),
legtr= c(1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,0,
0,0,0,0,0,0,1,0,0,0,0,0),
week7= c(0,0,0,0,0,0,1,0,0,0,0,0),
sex= c(1,1,1,1,1,1,0,0,0,0,0,0,0,0,1,1,1,
1,1,1,1,1,1,1,1,0,0,0))

# Initial values
list(
b0=c(200,200,200,200,200,200,200,200,200,200,
200,200,200,200,200,200,200,200,200,200,200,
200,200,200,200,200,200,200),
beta.c0=160,beta.c1=3,beta.c2=-6,beta.c3=26,
beta.c5=-4,beta.c6=107, beta.c7=1.9,beta.c8=
-0.8,beta.c9=1.3, beta.c10=1.2,beta.c11=-20,
isigmasq=1,beta.tau0=1,rho=0.9)
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(ii). Tumor Volume

model
{
mualpha ~ dnorm(0.0,1.0E-8)
mubeta~dnorm(0.0,1.0E-8)
taualpha

~ dgamma(0.0001,0.0001)

taudel

~ dgamma(0.0001,0.0001)

taugam

~ dgamma(0.0001,0.0001)

tau

~ dgamma(0.0001,0.0001)

taubeta

~ dgamma(0.0001,0.0001)

beta.c1 ~ dnorm(0.0,1.0E-8)
beta.c2 ~ dnorm(0.0,1.0E-8)
beta.c3 ~ dnorm(0.0,1.0E-8)
beta.c5 ~ dnorm(0.0,1.0E-8)
beta.c6 ~ dnorm(0.0,1.0E-8)
beta.c7 ~ dnorm(0.0,1.0E-8)
beta.c8 ~ dnorm(0.0,1.0E-8)
beta.c9 ~ dnorm(0.0,1.0E-8)
beta.c10 ~ dnorm(0.0,1.0E-8)
sig<-1/tau
sigalpha<-1/taualpha
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sigbeta<- 1/taubeta
for(i in 1 : N)
{
alpha[i]~dnorm(mualpha,taualpha)
beta[i]~dnorm(mubeta,taubeta)
for (k in 1:L)
{
del[i,k]~dnorm(alpha[i],taudel)
gam[i,k]~dnorm(beta[i],taugam)
for (j in 1:M)
{
logv[i,j,k]~dnorm(mu[i,j,k],tau)
mu[i,j,k] <- alpha[i] + del[i,k]+beta[i]*time[j]+
gam[i,k]*time[j]+ beta.c1*tmt2[i]+ beta.c2*tmt3[i]
+ beta.c3*tmt4[i]+ 0*tmt1[i]+ beta.c5*legtr[i]+
beta.c6*sex[i]+beta.c7*leg[k] +
beta.c8 * tmt2[i] * time[j] +
beta.c9 * tmt3[i] * time[j] +
beta.c10 * tmt4[i] * time[j]
}
}
}
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treatment2 <-beta.c1
treatment3 <- beta.c2
treatment4 <- beta.c3
leg_treated_untreated <-beta.c7
leg_left_right <- beta.c5
gender <- beta.c6
treatment2_time <- beta.c8
treatment3_time <-beta.c9
treatment4_time <- beta.c10
}

# Data
list(time=c(1,2,3,4,5,6,7,8,9,10,11,12), M=12,
N=28,L=2, logv=structure(.Data=c(
.
.
.
.
.
.
.Dim=c(28,12,2)),
tmt1=c(0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,
0,0,1,1,0,0,1,0),
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tmt2=c(0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,
1,1,0,0,0,1,0,0),
tmt3=c(1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,
0,0,0,0,1,0,0,0),
tmt4=c(0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,
0,0,0,0,0,0,0,1),
legtr= c(1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,0,
0,0,0,1,0,0,0,0,0),
sex=c(1,1,1,1,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,
1,1,1,1,1,0,0,0),
leg=c(0,1))

# Initial Values
list(alpha=c(0.1,0.12,0.13,0.14,0.15,0.16,0.17,0.18,
0.19,0.015, 0.215,0.315,0.415,0.515,0.615,0.715,
0.815,0.151,0.152,
0.153,0.154,0.155,0.156,0.157,0.185,0.915,0.4315,0.2315),
beta=c(0.21,0.22,0.23,0.24,0.25,0.26,0.27,0.28,0.29,0.12,
0.122,0.1232,0.1342,0.132,0.142,0.152,0.162,0.172,0.182,
0.192,0.212,0.222,0.232,0.242,0.252,0.262,0.272,0.282),
del=structure(.Data=c(0.1,0.12,0.13,0.14,0.15,0.16,
0.17,0.18,0.19,0.015,0.215,0.315,0.415,0.515,
0.615,0.715,0.815,
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0.151,0.152,0.153,0.154,0.155,0.156,0.157,0.185,0.915,
0.4315,0.2315,0.1215,0.6715,0.1,0.12,0.13,0.14,0.15,0.16,
0.17,0.18,0.19,0.015,0.215,0.315,0.415,0.515,0.615,0.715,
0.815,0.151,0.152,0.153,0.154,0.155,0.156,0.157,
0.185,0.915), .Dim=c(28,2)),
gam=structure(.Data=c(0.1,0.12,0.13,0.14,
0.15,0.16,0.17,0.18,
0.19,0.015,0.215,0.315,0.415,0.515,0.615,
0.715,0.815,0.151,
0.152,0.153,0.154,0.155,0.156,0.157,0.185,
0.915,0.4315,0.2315,
0.1215,0.6715,0.1,0.12,0.13,0.14,0.15,0.16,
0.17,0.18,0.19,0.015,
0.215,0.315,0.415,0.515,0.615,0.715,0.815,
0.151,0.152,0.153,
0.154,0.155,0.156,0.157,0.185,0.915),
.Dim=c(28,2)),
beta.c1=-0.05,beta.c2=0.07,beta.c3=0.11,beta.c5=-0.6,
beta.c6=-0.2,mubeta=0.33,taubeta=1,mualpha=-1.5,
taualpha=5,taugam=1,beta.c7=-0.15,beta.c8=0.02,
beta.c9=0.07,beta.c10=0.006,taubeta=262,taudel=5,
taugam=300,tau=6)
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(iii). Survival

model
{
for (i in 1:N)
{
surt [i] ~ dweib(p,mut [i]) I(surt.cen[i] , )
log(mut [i] ) <- beta2.c1+
beta2.c3 * tmt2[i] + beta2.c4 * tmt3[i] +
beta2.c5 * tmt4[i] +
beta2.c7*genderfem[i]
}

scale<- -(1/p)
intercept<- scale * beta2.c1
treatment2<- scale * (beta2.c3)
treatment3<- scale * (beta2.c4)
treatment4<- scale * (beta2.c5)
gender<- scale * (beta2.c7)

c2a<-beta2.c1+beta2.c3
median2male<-pow(log(2) * exp(-c2a),1/p)
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c2b<-beta2.c1+beta2.c3+beta2.c7
median2female<-pow(log(2) * exp(-c2b),1/p)
c3a<-beta2.c1+beta2.c4
median3male<-pow(log(2) * exp(-c3a),1/p)
c3b<-beta2.c1+beta2.c4+beta2.c7
median3female<-pow(log(2) * exp(-c3b),1/p)
c4a<-beta2.c1+beta2.c5
median4male<-pow(log(2) * exp(-c4a),1/p)
c4b<-beta2.c1+beta2.c5+beta2.c7
median4female<-pow(log(2) * exp(-c4b),1/p)
c100a<-beta2.c1
median100male<-pow(log(2) * exp(-c100a),1/p)
c100b<-beta2.c1+beta2.c7
median100female<-pow(log(2) * exp(-c100b),1/p)

p ~ dgamma(0.0001,0.0001)
beta2.c1 ~ dnorm(0,1.0E-8)
beta2.c3 ~ dnorm(0,1.0E-8)
beta2.c4 ~ dnorm(0,1.0E-8)
beta2.c5 ~ dnorm(0,1.0E-8)
beta2.c7 ~ dnorm(0,1.0E-8)
}
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#data
list(N=28,surt=c(
.
.
.
.
),
surt.cen=c(
.
.
.
.
),
genderfem=c( 0,0,0,0,0,0,1,1,1,1,1,1,1,1,0,0,0,0,0,
0,0,0,0,0,0,1,1,1),
tmt2=c( 0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,
0,0,0,1,0,0),
tmt3=c( 1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,
0,0,1,0,0,0),
tmt4=c( 0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,
0,0,0,0,0,1))

# initial values
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list(beta2.c1=0,beta2.c3=0,beta2.c4=0,
beta2.c5=0,p=4.8,beta2.c7=0)
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(iv). Joint Model

model
{
c1<-(isigmasq)/(1-pow(rho,2))
c2<-(isigmasq)*(1+pow(rho,2))/(1-pow(rho,2))
c3<-isigmasq*(-rho)/(1-pow(rho,2))
for (i in 1:M)
{
for (j in 1:M)
{
a1[i,j]<-step(1-i)*step(1-j)
b1[i,j]<-step(i-M)*step(j-M)
c1a[i,j]<-step(i-j)*step(j-i)
c1b[i,j]<-(1 - step(1-i)*step(1-j))
c1c[i,j]<-(1 - step(i-M)*step(j-M))
d1a[i,j]<-step(1-i+j)*step(1-j+i)
d1b[i,j]<-(1-step(i-j))*step(j-i)
e1a[i,j]<-step(1-j+i)*step(1-i+j)
e1b[i,j]<-(1-step(j-i))*step(i-j)
a[i,j]<-a1[i,j]*c1
b[i,j]<-b1[i,j]*c1
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c[i,j]<-c1a[i,j]*c1b[i,j]*c1c[i,j]*c2
d[i,j]<-d1a[i,j]*d1b[i,j]*c3
e[i,j]<-e1a[i,j]*e1b[i,j]*c3
tau[i,j]<- a[i,j]+b[i,j]+c[i,j]+d[i,j]+e[i,j]
}
}
for(k in 1 : N)
{
rmass[k,1:M]~dmnorm(mu[k,1:M],tau[1:M,1:M])
for (q in 1:M)
{
mu[k, q] <- b0 + beta.c1*tmt2[k]+ beta.c2*tmt3[k] +
beta.c3*tmt4[k]+ 0*tmt1[k]+beta.c5*legtr[k]
+beta.c6*sex[k] +beta.c7*time1[q] +
beta.c8*tmt2[k]*time1[q] + beta.c9*tmt3[k]*time1[q]
+ beta.c10*tmt4[k]*time1[q] + beta.c11 *week7[q] +U[k]
}

surt[k] ~ dweib(p,mut [k]) I(surt.cen[k] , )
log(mut [k] ) <- beta2.c1+ 0*tmt1[k]+
beta2.c3 * tmt2[k] + beta2.c4 * tmt3[k] +
beta2.c5 * tmt4[k] +
beta2.c7*genderfem[k] + r1*U[k]
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U[k] ~ dnorm(0,tauU0)
}
b0 ~ dnorm(0.0,1.0E-8)
tauU0 ~ dgamma(0.0001,0.0001)
r1 ~ dnorm(0.0,1.0E-8)
beta.c1 ~ dnorm(0.0,1.0E-8)
beta.c2 ~ dnorm(0.0,1.0E-8)
beta.c3 ~ dnorm(0.0,1.0E-8)
beta.c5 ~ dnorm(0.0,1.0E-8)
beta.c6 ~ dnorm(0.0,1.0E-8)
beta.c7 ~ dnorm(0.0,1.0E-8)
beta.c8 ~ dnorm(0.0,1.0E-8)
beta.c9 ~ dnorm(0.0,1.0E-8)
beta.c10 ~ dnorm(0.0,1.0E-8)
beta.c11 ~ dnorm(0.0,1.0E-8)
rho~dunif(-1,1)
isigmasq~dgamma(0.0001,0.0001)

intercept_mass<- b0
treatment2_mass<- beta.c1
treatment3_mass<- beta.c2
treatment4_mass<- beta.c3
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leg_left_right <- beta.c5
gender_mass <- beta.c6
time<- beta.c7
week_7 <- beta.c11
treatment2_time<- beta.c8
treatment3_time<- beta.c9
treatment4_time<- beta.c10
AR1<- rho

scale<-

-(1/p)

intercept_survival<- scale * beta2.c1
treatment2_survival<- scale * (beta2.c3)
treatment3_survival<- scale * (beta2.c4)
treatment4_survival<- scale * (beta2.c5)
gender_survival<- scale * (beta2.c7)
c2a<-beta2.c1+beta2.c3
median2male<-pow(log(2) * exp(-c2a),1/p)
c2b<-beta2.c1+beta2.c3+beta2.c7
median2female<-pow(log(2) * exp(-c2b),1/p)
c3a<-beta2.c1+beta2.c4
median3male<-pow(log(2) * exp(-c3a),1/p)
c3b<-beta2.c1+beta2.c4+beta2.c7
median3female<-pow(log(2) * exp(-c3b),1/p)
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c4a<-beta2.c1+beta2.c5
median4male<-pow(log(2) * exp(-c4a),1/p)
c4b<-beta2.c1+beta2.c5+beta2.c7
median4female<-pow(log(2) * exp(-c4b),1/p)
c100a<-beta2.c1
median100male<-pow(log(2) * exp(-c100a),1/p)
c100b<-beta2.c1+beta2.c7
median100female<-pow(log(2) * exp(-c100b),1/p)

p ~ dgamma(0.0001,0.0001)
beta2.c1 ~ dnorm(0,1.0E-8)
beta2.c3 ~ dnorm(0,1.0E-8)
beta2.c4 ~ dnorm(0,1.0E-8)
beta2.c5 ~ dnorm(0,1.0E-8)
beta2.c7 ~ dnorm(0,1.0E-8)
}
# data
list(time1=c(1,2,3,4,5,6,7,8,9,10,11,12), M=12, N=28,
rmass=structure(.Data=c(
.
.
.
.
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.Dim=c(28,12)),
tmt1= c( 0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,
0,0,1,1,0,0,1,0),
tmt2= c( 0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,
1,1,0,0,0,1,0,0),
tmt3= c( 1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,
0,0,0,0,1,0,0,0),
tmt4= c( 0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,
0,0,0,0,0,0,0,1),
legtr= c( 1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,0,
0,0,0,1,0,0,0,0,0),
week7= c(0,0,0,0,0,0,1,0,0,0,0,0),
sex= c( 1,1,1,1,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,
1,1,1,1,1,0,0,0),
surt=c(
.
.
.
.
),
surt.cen=c(
.
.
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.
.
),
genderfem=c( 0,0,0,0,0,0,1,1,1,1,1,1,1,1,0,0,0,0,
0,0,0,0,0,0,0,1,1,1))

# Initial Values
list(
b0=160,beta.c1=0.43,beta.c2=-8,beta.c3=26,beta.c5=3,
beta.c6=107, beta.c7=1.9,beta.c8=-0.7,beta.c9=1.4,
beta.c10=1.3,beta.c11=-20,
isigmasq=1,rho=0.9,
beta2.c1=22,beta2.c3=0,beta2.c4=0,
beta2.c5=0,p=4.8,beta2.c7=0,
tauU0=1, r1=0)
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Appendix C
MASS GRAPHS

Figure C.1: Posterior Distributions for selected coefficients in Mass model
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Figure C.2: Time series plots for selected coefficients in Mass model
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Figure C.3: Plots to demonstrate mixing for selected coefficients in Mass model
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Appendix D
TUMOR VOLUME GRAPHS

Figure D.1: Posterior Distributions for selected coefficients in Tumor volume model
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Figure D.2: Time Series plots for selected coefficients in Tumor volume model
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Figure D.3: Plots to demonstrate mixing for selected coefficients in Tumor volume
model
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Appendix E
SURVIVAL GRAPHS

Figure E.1: Posterior Distributions for selected coefficients in Survival model
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Figure E.2: Time Series plots for selected coefficients in Survival model
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Figure E.3: Plots to demonstrate mixing for selected coefficients in Survival model
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Appendix F
JOINT MODEL GRAPHS

Figure F.1: Posterior Distributions for selected coefficients of the Mass Submodel in
the Joint Model
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Figure F.2: Time Series plots for selected coefficients of the Mass Submodel in the
Joint Model
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Figure F.3: Plots to demonstrate mixing for selected coefficients of the Mass Submodel
in the Joint Model
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Figure F.4: Posterior Distributions for selected coefficients of the Survival Submodel
in the Joint Model
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Figure F.5: Time Series plots for selected coefficients of the Survival Submodel in the
Joint Model
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Figure F.6: Plots to demonstrate mixing for selected coefficients of the Survival Submodel in the Joint Model
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